PumaBiotech (@pumabiotech) / Twitter
Resumen: Puma Biotechnology y Pierre Fabre modifican el acuerdo de licencia de NERLYNX® para incluir la Gran China | Business Wire
Puma Biotechnology Reports Results of PB272 (neratinib) in P-III NALA Trial for Patients with 2L+ HER2+ Metastatic Breast Cancer #ASCO2019
Does Puma's quick Nerlynx launch play into its buyout prospects? | Fierce Pharma
Puma Biotechnology: Still Bullish At These Prices (NASDAQ:PBYI) | Seeking Alpha
PharmaBg
Puma – PHARMA
Compra Acciones de Puma Biotechnology Inc y Comprueba ($PBYI) su Precio de Mercado en eToro.
Puma Biotechnology: Too Little, Too Late, Too Much Of A Bad Side Effect (NASDAQ:PBYI) | Seeking Alpha
La EMA recomienda no aprobar el fármaco de Puma Biotech
PHARMA JONPI .: 08/24/14
Puma Wins 5-Year Extension of Patent on Main Breast Cancer Treatment Drug Nerlynx - Los Angeles Business Journal
Puma Biotechnology Surging
Ex-Puma exec charged with insider trading, hit with criminal charges | Fierce Biotech
Puma – PHARMA
Resumen: Puma Biotechnology y Pierre Fabre modifican el acuerdo de licencia de NERLYNX® para incluir la Gran China | Business Wire
PUMA BIOTECHNOLOGY, INC. : Precios y cotizaciones Acción | PBYI | US74587V1070 | MarketScreener
El negocio bursátil de PUMA BIOTECHNOLOGY – Observatorio de biopolitica
Puma Biotechnology
Puma Men – PHARMA
Puma Biotech Strikes Deal to Develop and Market its Breast Cancer Drug in China - Los Angeles Business Journal
Puma Biotech In-Licenses Takeda's Cancer Candidate With Primary Focus On Breast & Lung Cancer
Puma – PHARMA
Resumen: Puma Biotechnology y Pierre Fabre modifican el acuerdo de licencia de NERLYNX® para incluir la Gran China | Business Wire
Medical Affairs eLearning - MSL Society
